SNIBE Diagnostics specializes in a comprehensive range of diagnostic technologies, focusing on areas such as immunoassay, biochemistry, molecular diagnostics, and lab automation. Their product offerings include a broad menu of CLIA tests with 236 parameters, covering various medical fields such as thyroid function, tumor markers, autoimmune diseases, infectious diseases, and cardiac health. The company emphasizes innovation in diagnostic solutions, as evidenced by their participation in major medical conferences and the introduction of next-generation diagnostic technologies. SNIBE's commitment to quality is reflected in their extensive annual productivity of fully automated analyzers and reagent kits, which serve a global market.

In addition to their diagnostic products, SNIBE Diagnostics is dedicated to sustainability and corporate responsibility. They integrate Environmental, Social, and Governance (ESG) principles into their business strategy, focusing on energy efficiency and reducing carbon emissions. The company invests significantly in research and development, aiming to enhance their product offerings and maintain a competitive edge in the healthcare sector. SNIBE also prioritizes employee welfare and training, ensuring a supportive work environment while actively engaging in social responsibility initiatives, such as academic activities and global health conferences.

China

Snibe is a leading brand of Chemiluminescence immunoassay solution from Shenzhen, China. Also, Snibe is the first company who received FDA cleared on Chemiluminescence immunoassay product in China.

With more than 2600 staffs, Snibe has been focusing on Chemiluminescence immunoassay solution for 29 years. At present, Snibe's products have been widely exported to more than 150 countries with 30000 installations globally.

Best Quality, Best Service is our target. Snibe would like to be the pioneer in global diagnosis field.

SNIBE Diagnostics

Company Details